CIK 0001567514
ITCI Intra-Cellular Therapies, Inc.
Insider trading from SEC Form 4. Last filing Apr 2, 2025.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
9
with a Form 4 at this company
Signals
Open-market buys and sells at Intra-Cellular Therapies, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 15Weak | Sharon Mates Chairman and CEO sell | $8.7M 102,697 shares | -9% | - | |
| 30Weak | Michael Halstead President sell | $3.7M 41,583 shares | -182% | - |
Congressional trades
5 trades in ITCI disclosed by members of Congress under the STOCK Act. All congressional trades.
- Josh GottheimerHouse · D-NJ · last May 14, 20250 bought
3 sold - Gilbert Ray Cisneros, Jr.House · D-CA · last May 6, 20250 bought
2 sold
| Member | Trade | Asset | Reported range | Trade / filing date | Source |
|---|---|---|---|---|---|
Josh Gottheimer House · D-NJ | Sale | ITCI Intra-Cellular Therapies Inc. | $1,001 to $15k | Apr 3, 2025 / May 14, 2025 41 days after the trade | Clerk |
Gilbert Ray Cisneros, Jr. House · D-CA | Sale | ITCI Intra-Cellular Therapies Inc. | $1,001 to $15k | Apr 3, 2025 / May 6, 2025 33 days after the trade | Clerk |
Josh Gottheimer House · D-NJ | Partial sale | ITCI Intra-Cellular Therapies Inc. | $1,001 to $15k | Mar 17, 2025 / Apr 10, 2025 24 days after the trade | Clerk |
Gilbert Ray Cisneros, Jr. House · D-CA | Partial sale | ITCI Intra-Cellular Therapies Inc. | $1,001 to $15k | Mar 24, 2025 / Apr 7, 2025 14 days after the trade | Clerk |
Josh Gottheimer House · D-NJ | Partial sale | ITCI Intra-Cellular Therapies Inc. | $1,001 to $15k | Jan 24, 2025 / Feb 10, 2025 17 days after the trade | Clerk |
Transactions
The last 100 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Apr 2, 2025 | Eduardo Rene Salas director | DDisposition to issuer Common Stock | -1,567 | $132.00 | $207k | 0 | Apr 2, 2025 |
| Apr 2, 2025 | Sanjeev Narula Executive Vice President & CFO | DDisposition to issuer Stock Option (right to buy)derivative | -17,251 | - | - | 0 | Apr 2, 2025 |
| Apr 2, 2025 | Mark Neumann EVP, Chief Commercial Officer | DDisposition to issuer Common Stock | -52,811 | $132.00 | $7.0M | 0 | Apr 2, 2025 |
| Apr 2, 2025 | Robert L Van Nostrand director | DDisposition to issuer Common Stock | -11,340 | $132.00 | $1.5M | 0 | Apr 2, 2025 |
| Apr 2, 2025 | Joel S Marcus director | DDisposition to issuer Common Stock | -48,238 | $132.00 | $6.4M | 0 | Apr 2, 2025 |
| Apr 2, 2025 | Suresh K. Durgam EVP, Chief Medical Officer | DDisposition to issuer Common Stock | -42,913 | $132.00 | $5.7M | 0 | Apr 2, 2025 |
| Apr 2, 2025 | Michael Halstead President | DDisposition to issuer Common Stock | -21,307 | $132.00 | $2.8M | 0 | Apr 2, 2025 |
| Apr 2, 2025 | Sharon Mates Chairman and CEO | DDisposition to issuer Common Stock | -945,235 | $132.00 | $125M | 0 | Apr 2, 2025 |
| Apr 2, 2025 | Rory B Riggs director | DDisposition to issuer Common Stock | -131,512 | $132.00 | $17M | 0 | Apr 2, 2025 |
| Apr 2, 2025 | Rory B Riggs director | DDisposition to issuer Stock Option (right to buy)derivative | -20,000 | - | - | 0 | Apr 2, 2025 |
| Apr 2, 2025 | Eduardo Rene Salas director | DDisposition to issuer Stock Option (right to buy)derivative | -20,000 | - | - | 0 | Apr 2, 2025 |
| Apr 2, 2025 | Mark Neumann EVP, Chief Commercial Officer | DDisposition to issuer Stock Option (right to buy)derivative | -17,916 | - | - | 0 | Apr 2, 2025 |
| Apr 2, 2025 | Michael Halstead President | DDisposition to issuer Stock Option (right to buy)derivative | -40,472 | - | - | 0 | Apr 2, 2025 |
| Apr 2, 2025 | Suresh K. Durgam EVP, Chief Medical Officer | DDisposition to issuer Stock Option (right to buy)derivative | -53,967 | - | - | 0 | Apr 2, 2025 |
| Apr 2, 2025 | Robert L Van Nostrand director | DDisposition to issuer Stock Option (right to buy)derivative | -20,000 | - | - | 0 | Apr 2, 2025 |
| Apr 2, 2025 | Sharon Mates Chairman and CEO | DDisposition to issuer Common Stockindirect: By the Sharon Mates Family Foundation | -190,000 | $132.00 | $25M | 0 | Apr 2, 2025 |
| Apr 2, 2025 | Joel S Marcus director | DDisposition to issuer Common Stockindirect: See Footnote | -10,000 | $132.00 | $1.3M | 0 | Apr 2, 2025 |
| Apr 2, 2025 | Sanjeev Narula Executive Vice President & CFO | DDisposition to issuer Restricted Stock Unitsderivative | -35,046 | - | - | 0 | Apr 2, 2025 |
| Apr 2, 2025 | Rory B Riggs director | DDisposition to issuer Stock Option (right to buy)derivative | -20,000 | - | - | 0 | Apr 2, 2025 |
| Apr 2, 2025 | Sharon Mates Chairman and CEO | DDisposition to issuer Stock Option (right to buy)derivative | -86,003 | - | - | 0 | Apr 2, 2025 |
| Apr 2, 2025 | Joel S Marcus director | DDisposition to issuer Stock Option (right to buy)derivative | -4,322 | - | - | 0 | Apr 2, 2025 |
| Apr 2, 2025 | Eduardo Rene Salas director | DDisposition to issuer Stock Option (right to buy)derivative | -16,757 | - | - | 0 | Apr 2, 2025 |
| Apr 2, 2025 | Mark Neumann EVP, Chief Commercial Officer | DDisposition to issuer Restricted Stock Unitsderivative | -13,133 | - | - | 0 | Apr 2, 2025 |
| Apr 2, 2025 | Sanjeev Narula Executive Vice President & CFO | DDisposition to issuer Restricted Stock Unitsderivative | -22,727 | - | - | 0 | Apr 2, 2025 |
| Apr 2, 2025 | Michael Halstead President | DDisposition to issuer Stock Option (right to buy)derivative | -17,916 | - | - | 0 | Apr 2, 2025 |
| Apr 2, 2025 | Suresh K. Durgam EVP, Chief Medical Officer | DDisposition to issuer Stock Option (right to buy)derivative | -33,443 | - | - | 0 | Apr 2, 2025 |
| Apr 2, 2025 | Robert L Van Nostrand director | DDisposition to issuer Stock Option (right to buy)derivative | -20,000 | - | - | 0 | Apr 2, 2025 |
| Apr 2, 2025 | Rory B Riggs director | DDisposition to issuer Stock Option (right to buy)derivative | -20,000 | - | - | 0 | Apr 2, 2025 |
| Apr 2, 2025 | Sharon Mates Chairman and CEO | DDisposition to issuer Stock Option (right to buy)derivative | -135,399 | - | - | 0 | Apr 2, 2025 |
| Apr 2, 2025 | Eduardo Rene Salas director | DDisposition to issuer Stock Option (right to buy)derivative | -7,009 | - | - | 0 | Apr 2, 2025 |
| Apr 2, 2025 | Mark Neumann EVP, Chief Commercial Officer | DDisposition to issuer Restricted Stock Unitsderivative | -17,485 | - | - | 0 | Apr 2, 2025 |
| Apr 2, 2025 | Suresh K. Durgam EVP, Chief Medical Officer | DDisposition to issuer Stock Option (right to buy)derivative | -18,714 | - | - | 0 | Apr 2, 2025 |
| Apr 2, 2025 | Joel S Marcus director | DDisposition to issuer Restricted Stock Unitsderivative | -2,951 | - | - | 0 | Apr 2, 2025 |
| Apr 2, 2025 | Robert L Van Nostrand director | DDisposition to issuer Stock Option (right to buy)derivative | -20,000 | - | - | 0 | Apr 2, 2025 |
| Apr 2, 2025 | Michael Halstead President | DDisposition to issuer Restricted Stock Unitsderivative | -13,133 | - | - | 0 | Apr 2, 2025 |
| Apr 2, 2025 | Eduardo Rene Salas director | DDisposition to issuer Stock Option (right to buy)derivative | -4,322 | - | - | 0 | Apr 2, 2025 |
| Apr 2, 2025 | Michael Halstead President | DDisposition to issuer Restricted Stock Unitsderivative | -24,478 | - | - | 0 | Apr 2, 2025 |
| Apr 2, 2025 | Suresh K. Durgam EVP, Chief Medical Officer | DDisposition to issuer Stock Option (right to buy)derivative | -17,916 | - | - | 0 | Apr 2, 2025 |
| Apr 2, 2025 | Mark Neumann EVP, Chief Commercial Officer | DDisposition to issuer Restricted Stock Unitsderivative | -22,727 | - | - | 0 | Apr 2, 2025 |
| Apr 2, 2025 | Rory B Riggs director | DDisposition to issuer Stock Option (right to buy)derivative | -20,000 | - | - | 0 | Apr 2, 2025 |
| Apr 2, 2025 | Robert L Van Nostrand director | DDisposition to issuer Stock Option (right to buy)derivative | -20,000 | - | - | 0 | Apr 2, 2025 |
| Apr 2, 2025 | Sharon Mates Chairman and CEO | DDisposition to issuer Stock Option (right to buy)derivative | -138,473 | - | - | 0 | Apr 2, 2025 |
| Apr 2, 2025 | Eduardo Rene Salas director | DDisposition to issuer Restricted Stock Unitsderivative | -2,951 | - | - | 0 | Apr 2, 2025 |
| Apr 2, 2025 | Michael Halstead President | DDisposition to issuer Restricted Stock Unitsderivative | -45,454 | - | - | 0 | Apr 2, 2025 |
| Apr 2, 2025 | Rory B Riggs director | DDisposition to issuer Stock Option (right to buy)derivative | -16,757 | - | - | 0 | Apr 2, 2025 |
| Apr 2, 2025 | Mark Neumann EVP, Chief Commercial Officer | AGrant or award Performance Stock Unitsderivative | +13,134 | $0.00 | $0 | 13,134 | Apr 2, 2025 |
| Apr 2, 2025 | Suresh K. Durgam EVP, Chief Medical Officer | DDisposition to issuer Restricted Stock Unitsderivative | -13,133 | - | - | 0 | Apr 2, 2025 |
| Apr 2, 2025 | Robert L Van Nostrand director | DDisposition to issuer Stock Option (right to buy)derivative | -20,000 | - | - | 0 | Apr 2, 2025 |
| Apr 2, 2025 | Sharon Mates Chairman and CEO | DDisposition to issuer Stock Option (right to buy)derivative | -66,886 | - | - | 0 | Apr 2, 2025 |
| Apr 2, 2025 | Sharon Mates Chairman and CEO | DDisposition to issuer Stock Option (right to buy)derivative | -53,471 | - | - | 0 | Apr 2, 2025 |
| Apr 2, 2025 | Rory B Riggs director | DDisposition to issuer Stock Option (right to buy)derivative | -7,009 | - | - | 0 | Apr 2, 2025 |
| Apr 2, 2025 | Michael Halstead President | AGrant or award Performance Stock Unitsderivative | +13,134 | $0.00 | $0 | 13,134 | Apr 2, 2025 |
| Apr 2, 2025 | Mark Neumann EVP, Chief Commercial Officer | DDisposition to issuer Performance Stock Unitsderivative | -13,134 | - | - | 0 | Apr 2, 2025 |
| Apr 2, 2025 | Robert L Van Nostrand director | DDisposition to issuer Stock Option (right to buy)derivative | -16,757 | - | - | 0 | Apr 2, 2025 |
| Apr 2, 2025 | Suresh K. Durgam EVP, Chief Medical Officer | DDisposition to issuer Restricted Stock Unitsderivative | -17,485 | - | - | 0 | Apr 2, 2025 |
| Apr 2, 2025 | Sharon Mates Chairman and CEO | DDisposition to issuer Stock Option (right to buy)derivative | -50,167 | - | - | 0 | Apr 2, 2025 |
| Apr 2, 2025 | Suresh K. Durgam EVP, Chief Medical Officer | DDisposition to issuer Restricted Stock Unitsderivative | -24,621 | - | - | 0 | Apr 2, 2025 |
| Apr 2, 2025 | Rory B Riggs director | DDisposition to issuer Stock Option (right to buy)derivative | -4,322 | - | - | 0 | Apr 2, 2025 |
| Apr 2, 2025 | Michael Halstead President | DDisposition to issuer Performance Stock Unitsderivative | -13,134 | - | - | 0 | Apr 2, 2025 |
| Apr 2, 2025 | Mark Neumann EVP, Chief Commercial Officer | AGrant or award Performance Stock Unitsderivative | +8,742 | $0.00 | $0 | 8,742 | Apr 2, 2025 |
| Apr 2, 2025 | Robert L Van Nostrand director | DDisposition to issuer Stock Option (right to buy)derivative | -7,009 | - | - | 0 | Apr 2, 2025 |
| Apr 2, 2025 | Sharon Mates Chairman and CEO | DDisposition to issuer Restricted Stock Unitsderivative | -40,713 | - | - | 0 | Apr 2, 2025 |
| Apr 2, 2025 | Rory B Riggs director | DDisposition to issuer Restricted Stock Unitsderivative | -2,951 | - | - | 0 | Apr 2, 2025 |
| Apr 2, 2025 | Suresh K. Durgam EVP, Chief Medical Officer | AGrant or award Performance Stock Unitsderivative | +13,134 | $0.00 | $0 | 13,134 | Apr 2, 2025 |
| Apr 2, 2025 | Michael Halstead President | AGrant or award Performance Stock Unitsderivative | +12,240 | $0.00 | $0 | 12,240 | Apr 2, 2025 |
| Apr 2, 2025 | Mark Neumann EVP, Chief Commercial Officer | DDisposition to issuer Performance Stock Unitsderivative | -8,742 | - | - | 0 | Apr 2, 2025 |
| Apr 2, 2025 | Robert L Van Nostrand director | DDisposition to issuer Stock Option (right to buy)derivative | -4,322 | - | - | 0 | Apr 2, 2025 |
| Apr 2, 2025 | Sharon Mates Chairman and CEO | DDisposition to issuer Restricted Stock Unitsderivative | -69,940 | - | - | 0 | Apr 2, 2025 |
| Apr 2, 2025 | Suresh K. Durgam EVP, Chief Medical Officer | DDisposition to issuer Performance Stock Unitsderivative | -13,134 | - | - | 0 | Apr 2, 2025 |
| Apr 2, 2025 | Michael Halstead President | DDisposition to issuer Performance Stock Unitsderivative | -12,240 | - | - | 0 | Apr 2, 2025 |
| Apr 2, 2025 | Robert L Van Nostrand director | DDisposition to issuer Restricted Stock Unitsderivative | -2,951 | - | - | 0 | Apr 2, 2025 |
| Apr 2, 2025 | Sharon Mates Chairman and CEO | DDisposition to issuer Restricted Stock Unitsderivative | -121,212 | - | - | 0 | Apr 2, 2025 |
| Apr 2, 2025 | Suresh K. Durgam EVP, Chief Medical Officer | AGrant or award Performance Stock Unitsderivative | +8,742 | $0.00 | $0 | 8,742 | Apr 2, 2025 |
| Apr 2, 2025 | Sharon Mates Chairman and CEO | AGrant or award Performance Stock Unitsderivative | +40,712 | $0.00 | $0 | 40,712 | Apr 2, 2025 |
| Apr 2, 2025 | Suresh K. Durgam EVP, Chief Medical Officer | DDisposition to issuer Performance Stock Unitsderivative | -8,742 | - | - | 0 | Apr 2, 2025 |
| Apr 2, 2025 | Sharon Mates Chairman and CEO | DDisposition to issuer Performance Stock Unitsderivative | -40,712 | - | - | 0 | Apr 2, 2025 |
| Apr 2, 2025 | Sharon Mates Chairman and CEO | AGrant or award Performance Stock Unitsderivative | +34,970 | $0.00 | $0 | 34,970 | Apr 2, 2025 |
| Apr 2, 2025 | Sharon Mates Chairman and CEO | DDisposition to issuer Performance Stock Unitsderivative | -34,970 | - | - | 0 | Apr 2, 2025 |
| Mar 26, 2025 | Sharon Mates Chairman and CEO | GGift Common Stock | -190,000 | $0.00 | $0 | 945,235 | Mar 31, 2025 |
| Mar 26, 2025 | Sharon Mates Chairman and CEO | GGift Common Stockindirect: By the Sharon Mates Family Foundation | +190,000 | $0.00 | $0 | 190,000 | Mar 31, 2025 |
| Mar 6, 2025 | Suresh K. Durgam EVP, Chief Medical Officer | MOption exercise Common Stock | +13,133 | - | - | 44,256 | Mar 10, 2025 |
| Mar 6, 2025 | Michael Halstead President | MOption exercise Common Stock | +13,133 | - | - | 24,437 | Mar 10, 2025 |
| Mar 6, 2025 | Mark Neumann EVP, Chief Commercial Officer | MOption exercise Common Stock | +13,133 | - | - | 54,154 | Mar 10, 2025 |
| Mar 6, 2025 | Sharon Mates Chairman and CEO | MOption exercise Common Stock | +40,712 | - | - | 1,144,646 | Mar 10, 2025 |
| Mar 6, 2025 | Suresh K. Durgam EVP, Chief Medical Officer | FTax withholding Common Stock | -5,572 | $131.19 | $731k | 38,684 | Mar 10, 2025 |
| Mar 6, 2025 | Sharon Mates Chairman and CEO | FTax withholding Common Stock | -19,848 | $131.19 | $2.6M | 1,124,798 | Mar 10, 2025 |
| Mar 6, 2025 | Michael Halstead President | FTax withholding Common Stock | -6,718 | $131.19 | $881k | 17,719 | Mar 10, 2025 |
| Mar 6, 2025 | Mark Neumann EVP, Chief Commercial Officer | FTax withholding Common Stock | -5,572 | $131.19 | $731k | 48,582 | Mar 10, 2025 |
| Mar 10, 2025 | Suresh K. Durgam EVP, Chief Medical Officer | MOption exercise Common Stock | +7,345 | - | - | 46,029 | Mar 10, 2025 |
| Mar 10, 2025 | Michael Halstead President | MOption exercise Common Stock | +7,345 | - | - | 25,064 | Mar 10, 2025 |
| Mar 10, 2025 | Mark Neumann EVP, Chief Commercial Officer | MOption exercise Common Stock | +7,345 | - | - | 55,927 | Mar 10, 2025 |
| Mar 10, 2025 | Sharon Mates Chairman and CEO | MOption exercise Common Stock | +20,566 | - | - | 1,145,364 | Mar 10, 2025 |
| Mar 10, 2025 | Suresh K. Durgam EVP, Chief Medical Officer | FTax withholding Common Stock | -3,116 | $131.24 | $409k | 42,913 | Mar 10, 2025 |
| Mar 10, 2025 | Michael Halstead President | FTax withholding Common Stock | -3,757 | $131.24 | $493k | 21,307 | Mar 10, 2025 |
| Mar 10, 2025 | Mark Neumann EVP, Chief Commercial Officer | FTax withholding Common Stock | -3,116 | $131.24 | $409k | 52,811 | Mar 10, 2025 |
| Mar 10, 2025 | Sharon Mates Chairman and CEO | FTax withholding Common Stock | -10,129 | $131.24 | $1.3M | 1,135,235 | Mar 10, 2025 |
| Mar 6, 2025 | Suresh K. Durgam EVP, Chief Medical Officer | MOption exercise Restricted Stock Unitsderivative | -13,133 | $0.00 | $0 | 13,133 | Mar 10, 2025 |
| Mar 6, 2025 | Sharon Mates Chairman and CEO | MOption exercise Restricted Stock Unitsderivative | -40,712 | $0.00 | $0 | 40,713 | Mar 10, 2025 |
| Mar 6, 2025 | Mark Neumann EVP, Chief Commercial Officer | MOption exercise Restricted Stock Unitsderivative | -13,133 | $0.00 | $0 | 13,133 | Mar 10, 2025 |
| Mar 6, 2025 | Michael Halstead President | MOption exercise Restricted Stock Unitsderivative | -13,133 | $0.00 | $0 | 13,133 | Mar 10, 2025 |
Insiders
Everyone who has filed a Form 4 here.
- Suresh K. DurgamEVP, Chief Medical Officer
- Michael HalsteadPresident
- Joel S Marcuschair, officer, director
- Sharon MatesChairman and CEO
- Sanjeev NarulaExecutive Vice President & CFO
- Mark NeumannEVP, Chief Commercial Officer
- Rory B Riggsdirector, ceo, officer, owner
- Eduardo Rene Salasdirector
- Robert L Van Nostranddirector
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.